CLINICAL RESPONSES TO GEFITINIB RETREATMENT IN NON-SMALL-CELL-LUNG-CANCER ADENOCARCINOMA PATIENTS WHO BENEFITED FROM PRIOR EFFECTIVE GEFITINIB THERAPY: A RETROSPECTIVE ANALYSIS

被引：0
|
作者：
Li, Junling [1 ]
Yan, Wang [1 ]
Yuankai, Shi [1 ]
机构：
[1] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
gefitinb; NSCLC; adenocarcinoma; readministration;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1291 / S1292
页数：2
相关论文
共 50 条
  • [1] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
    Watanabe, Satoshi
    Tanaka, Junta
    Ota, Takeshi
    Kondo, Rie
    Tanaka, Hiroshi
    Kagamu, Hiroshi
    Ichikawa, Kosuke
    Koshio, Jun
    Baba, Junko
    Miyabayashi, Takao
    Narita, Ichiei
    Yoshizawa, Hirohisa
    BMC CANCER, 2011, 11
  • [2] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
    Satoshi Watanabe
    Junta Tanaka
    Takeshi Ota
    Rie Kondo
    Hiroshi Tanaka
    Hiroshi Kagamu
    Kosuke Ichikawa
    Jun Koshio
    Junko Baba
    Takao Miyabayashi
    Ichiei Narita
    Hirohisa Yoshizawa
    BMC Cancer, 11
  • [3] Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy
    Watanabe, S.
    Saida, Y.
    Ichikawa, K.
    Koshio, J.
    Baba, J.
    Miura, S.
    Tanaka, J.
    Kagamu, H.
    Narita, I.
    Yoshizawa, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S618 - S619
  • [4] Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study
    Yu, Shufei
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Wang, Bin
    Wang, Ziping
    Zhang, Xiangru
    Shi, Yuankai
    THORACIC CANCER, 2013, 4 (02) : 109 - 116
  • [5] RETROSPECTIVE ANALYSIS FOR CLINICAL CHARACTERISTICS OF ACQUIRED RESISTANCE TO GEFITINIB IN NON-SMALL CELL LUNG CANCER PATIENTS
    Kim, Hye Ryun
    Kim, Young Chul
    Kim, Kyu Sik
    Ban, Hee Jung
    Lee, Sung Yong
    Jang, Tae Won
    Shin, Kyeong Cheol
    Lee, Gwan Ho
    Ryu, Jeong Seon
    Jang, Seung Hoon
    Lee, Jeong Eun
    Kim, Sun Young
    Kim, Hee Joung
    Young, Kye
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S665 - S665
  • [6] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [7] Gefitinib Monotherapy in Advanced non-small-cell Lung Cancer: A Retrospective Analysis
    Shrestha, S.
    Joshi, P.
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2012, 52 (02) : 66 - 71
  • [8] Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study
    Oh, In-Jae
    Ban, Hee-Jung
    Kim, Kyu-Sik
    Kim, Young-Chul
    LUNG CANCER, 2012, 77 (01) : 121 - 127
  • [9] Gefitinib (ZD1839) as compassionate use therapy in patients (pts) with advanced non-small-cell-lung-cancer (NSCLC) after failing prior chemotherapy.
    Santo, A
    Salmaso, F
    Giovannini, M
    Oliani, C
    Toso, S
    Zovato, S
    Calabrò, F
    Terzi, A
    Cartei, G
    Cetto, GL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 697S - 697S
  • [10] Gefitinib therapy for advanced non-small-cell lung cancer
    Liu, CY
    Seen, S
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1644 - 1653
12345